Acta Scientific Medical Sciences (ASMS)(ISSN: 2582-0931)

Review Article Volume 6 Issue 2

The Key Aspects of BRCA1 Interactome for Novel Breast Cancer Therapies

Raji Sundararajan* and Ignacio G Camarillo

Purdue University, West Lafayette, USA

*Corresponding Author: Raji Sundararajan, Purdue University, West Lafayette, USA

Received: November 30, 2021; Published: January 12, 2022

Abstract

In Feb 2021, World Health Organization (WHO) announced that breast cancer overtook lung cancer as the #1 cancer in the world. With over 2 million new cases and over 600,000 deaths in 2020, breast cancer is the most common cancer of women worldwide. About 10% of the breast cancer is familial (or hereditary), caused by mutations of Breast Cancer Susceptibility gene 1, commonly known as BRCA1. Located in chromosome 17, this gene has multiple functions, interactions, pathways and direct and indirect binding partners, contributing to the various hall marks of cancer, including cell cycle and other. It interacts with several genes and proteins and these interactions are studied using String diagrams. The goal is to obtain better insights of the various key aspects of these interactions and utilize them towards novel breast cancer therapies for familial breast cancer treatments.

Keywords: BRCA1; Breast Cancer; Familial; String Diagram; Gene Ontology; Pathways

References

  1. R Roy., et al. “BRCA1 and BRCA2: different roles in a common pathway of genome protection”. Nature Reviews-Cancer (2012): 12.
  2. , et al. “Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular types”. Scientific Reports 10 (2020): 7073.
  3. RI Yarden and MZ Papa. “BRCA1 at the crossroad of multiple cellular pathways: approaches for therapeutic interventions”. Molecular Cancer Therapeutics 6 (2006).
  4. , et al. “Breast and Ovarian cancer incidence in BRCA1-mutation”. American Journal of Human Genetics (1995): 56.
  5. , et al. “Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer”. Breast Cancer Research and Treatment (2016): 158.
  6. , et al. “Breast and ovarian cancer incidence in BRCA-1 mutation”. American Journal of Human Genetics 56 (1995): 265-271.
  7. , et al. “Clinical outcomes of breast cancer in carriers of BRCA1 and bRCA2 mutations”. The New England Journal of Medicine 357.2 (2007).
  8. Turnbull C and Rahman R. “Genetic predisposition to breast cancer: Past, present, and Future”. Annual Review of Genomics and Human Genetics 9 (2008): 321-345.
  9. https://www.ncbi.nlm.gov/gene/672.
  10. Godet I and Gilkes DM. “BRCA1 and BRCA2 mutations and treatment strategies for breast cancer". Integrative Cancer Science and Therapeutics (2017).
  11. , et al. “A strong candidate for the 17q-linked breast and ovarian cancer susceptibility gene BRCA1”. Science 266 (1994): 66-71.
  12. Rosen EM., et al. “BRCA1 regulation of transcription”. Cancer Letters 236 (2006): 175-185.
  13. , et al. “BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures”. Genes and Development 14 (2000): 927-939.
  14. Rouillard AD., et al. “The harmonizome: a collection of processed datasets gathered to serve and mine knowledge about genes and proteins”. Database (Oxford) (2006).
  15. http://www.au-kbc.org/research_areas/bio/projects/bcinfo/gen/bcgenetics1.html.
  16. , et al. “Characterization of BRCA1 Ring Finger variants of uncertain significance”. Breast Cancer Research Treatment 119.3 (2010): 737-743.
  17. Duncan JA., et al. “BRCA1 and BRCA2 proteins: roles in health and disease”. Molecular Pathology: MP5 (1998): 237-247.
  18. Gudmundsdottir K and Ashworth A. “The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability”. Oncogene43 (2006): 5864-5874.
  19. Chavez KJ., et al. “Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer”. Breast Disease1-2 (201): 35-48.
  20. Deininger P. “Genetic instability in cancer: Caretaker and Gatekeeper genes”. The Ochsner Journal 4 (1999): 206-209.
  21. https://www.abeomics.com/brca1-pathway.
  22. string-db.org.
  23. https://www.kegg.jp/kegg-bin/show_pathway?hsa04330.
  24. , et al. “The Notch pathway in breast cancer progression”. The Scientific World Journal (2018).
  25. , et al. “Notch signaling in Breast cancer: From pathway analysis to therapy”. Cancer Letter 461 (2019): 123-131.
  26. , et al. “BRCA1 is a key regulator of breast differentiation through activation of Notch signaling with implications for anti-endocrine treatment of breast cancers”. Nucleic Acids Research 41.18 (2013).
  27. L Fitzgerald. “The roles of P53, BRCA1, and PTEN in hereditary cancers” (2021).
  28. Murthy P and Muggia F. “Women’s cancers: how the discovery of BRCA1 is driving current concepts of cancer biology and therapeutics”. Ecancer 13 (2019): 904.
  29. https://www.kegg.jp/kegg-bin/show_pathway?hsa03440.
  30. Savage KI and Harkin DP. “BRCA1, a ‘complex’ protein involved in the maintenance of genomic stability”. FEBS Journal 282 (2015): 630-646.
  31. Dai X., et al. “Breast cancer cell line classification and its relevance with breast tumor subtyping". Journal of Cancer16 (2017): 3131-3141.
  32. Mittal L., et al. “Electrical pulse-mediated Veliparib for the treatment of triple negative breast cancer: An in vitro model study”. International Journal on Current Research and Academic Review3 (2017): 53-64.
  33. Lee J., et al. “Abstract A249: Navitoclax and veliparib yield cytotoxicity with lower doses than used for single agents in women's cancers”. Molecular Cancer Therapeutics11 (2013).

Citation

Citation: Raji Sundararajan and Ignacio G Camarillo., et al. “The Neonates' Body Length and Body Weight in Two Different Periods of Time”.Acta Scientific Medical Sciences 6.2 (2022): 65-73.

Copyright

Copyright: © 2022 Raji Sundararajan and Ignacio G Camarillo., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.403

Indexed In





News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is December 15, 2022.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US